The Unblinding: Has Lilly Solved the Alzheimer’s Puzzle? — An Epilogue
The search continues.
Adam Wren
Read More
The Unblinding: Has Lilly Solved The Alzheimer’s Puzzle?
Eli Lilly and Company has spent three decades and $3 billion in an Ahab-like quest to develop the world’s first effective drug to treat Alzheimer’s disease.
Adam Wren
Read More
Life after Zyprexa: the Future of Eli Lilly and Company
“We want high quality of life as long as possible, don’t we?” says Lilly executive Jan Lundberg. “Many of our current diseases are chronic, and they accumulate with age, so there are major demands coming from the aging population.”
Evan West
Read More
Side Effects
With thousands of medical success stories and billions in revenue, officials at Lilly are still celebrating the success of Zyprexa. But its troubled path reveals volumes about how difficult bringing even an approved medication to market can turn out to be.